Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
INVA
INVA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INVA News
INVA Stock Fluctuates: 52-Week Low at $16.52
Jan 06 2026
NASDAQ.COM
FDA Greenlights Innoviva's NUZOLVENCE, the First Oral Treatment for Gonorrhea
Dec 13 2025
NASDAQ.COM
Innoviva Receives FDA Approval for NUZOLVENCE to Treat Gonorrhea
Dec 12 2025
Newsfilter
Innoviva Reports Positive Phase 3 Results for Zoliflodacin in Treating Gonorrhea
Dec 12 2025
Businesswire
Innoviva Publishes Positive Phase 3 Results for Zoliflodacin in Gonorrhea Treatment
Dec 12 2025
Newsfilter
Biotech Stocks Await FDA Verdict in December 2025
Nov 27 2025
NASDAQ.COM
Cantor Fitzgerald Keeps Overweight Rating on Innoviva, Increases Price Target to $31
Nov 06 2025
Benzinga
Innoviva, Inc. Announces Rise in Q3 Earnings
Nov 06 2025
NASDAQ.COM
In-Depth Insights: 5 Analysts Weigh in on Innoviva Stock
Sep 30 2025
Benzinga
Expert Outlook: Innoviva Through The Eyes Of 4 Analysts
Aug 11 2025
Benzinga
Innoviva (INVA) Q2 Sales Jump 64%
Aug 07 2025
NASDAQ.COM
Relative Strength Alert For Innoviva
Jul 28 2025
NASDAQ.COM
This Cisco Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Jul 14 2025
Benzinga
First Week of August 15th Options Trading For Innoviva (INVA)
Jun 23 2025
NASDAQ.COM
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025
Jun 12 2025
Newsfilter
FDA Grants Priority Review For Innoviva's Zoliflodacin For Treatment Of Uncomplicated Gonorrhea
Jun 12 2025
NASDAQ.COM
Show More News
